- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02251171
Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult Volunteers
A Single-centre Open-label Study in Healthy Adult Volunteers to Determine the Effects of Steady-state TPV/RTV (500 mg/200 mg) on the Single-dose Pharmacokinetics of Rifabutin (MYCOBUTIN®) 150 mg, and the Effects of Single-dose Rifabutin (150 mg) on the Steady-state Pharmacokinetics of TPV 500 mg (Co-administered With RTV 200 mg)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects between 18 and 60 years of age inclusive
- A Body Mass Index (BMI) between 18 and 29 kg/m2
- Signed informed consent prior to trial participation
- Ability to swallow multiple large capsules without difficulty
- Acceptable laboratory values that indicate adequate baseline organ function are required at the time of screening. Laboratory values are considered to be acceptable if severity was less than or equal to Grade 1, based on the AIDS Clinical Trials Group (ACTG) Grading Scale. All abnormal laboratory values greater than Grade 1 are subject to approval by the trial clinical monitor
- Acceptable medical history, physical examination, and 12-lead ECG are required prior to entering the treatment phase of the study. The requirement for chest X-ray is left to the investigator's discretion
Willingness to abstain from the following starting 14 days prior to any administration of study drug up until the end of the study:
- Grapefruit or grapefruit juice
- Red wine
- Seville oranges
- St. John's Wort or Milk Thistle
- Willingness to abstain from alcohol starting 2 days prior to administration of any study drug up to the end of the study
Willingness to abstain from the following within 72 hours of pharmacokinetic (PK) sampling:
- Garlic supplements
- Methylxanthine containing drinks (coffee, tea, cola, energy drinks, chocolate, etc.)
- Willingness to abstain from over the counter herbal medications for the duration of the study
- Have been non-smokers for 3 months
- Willingness to abstain from vigorous physical exercise during intensive PK study Days 1, 14, and 15
- Reasonable probability for completion of the study
Exclusion Criteria:
As a guideline, subjects who have abnormal laboratory values at screening, and who are taking prescription medications are excluded:
Female subjects with reproductive potential who:
- Have positive serum β-human chorionic gonadotropin at Visit 1, or on study Day 0 or study Day 1
- Have not been using a barrier contraceptive method for at least 3 months prior to Visit 3 (study Day 1)
- Are not willing to use a reliable method of barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during the trial and 60 days after completion/termination
- Are breast-feeding
- Participation in another trial with an investigational medicine within 60 days prior to study Day 0 (Visit 2)
- Use of any medication listed in Protocol within 30 days prior to study Day 0 (Visit 2)
- Use of any pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month prior to study Day 0 and for the duration of the study. Use of Depo-Provera is excluded for six months prior to study Day 0
- Use of hormone replacement therapy within 1 month prior to study Day 0 and for the duration of the study
- Administration of antibiotics within 10 days prior to study Day 0 (Visit 2) or during the trial
- History of acute illness within sixty (60) days of study Day 0. Subjects are excluded if they have an acute illness greater than sixty days prior to study Day 0 if, in the opinion of the investigator, the subject did not qualify as a healthy volunteer
- History of thrombotic disease
- History of migraine headache
- Have serological evidence of hepatitis B or C virus
- Have serological evidence of exposure to HIV
- Recent history of alcohol or substance abuse (within 1 year of screening)
- Blood or plasma donations within 30 days prior to study Day 0 (Visit 2) or during the trial
- Subjects with a seated systolic blood pressure either <100 mm Hg or >150 mm Hg; resting heart rate either <50 beats/min or >90 beats/min. For subjects with a resting heart rate below 50, or above 90, the investigator may discuss their exclusion with the clinical monitor on a case-by-case basis
- Subjects with history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering TPV, RTV or RFB to the subject
- Subjects who have taken (within 7 days prior to study Day 0) or are taking any over-the-counter or prescription drug that, in the opinion of the investigator in consultation with the clinical monitor, might interfere with either the absorption, distribution or metabolism of the test substances
- Known hypersensitivity to TPV, RTV, RFB, or sulphonamide class of drugs
- Inability to adhere to the protocol
- Cautions or warnings in the RTV and RFB package insert which, in the judgment of the investigator, should exclude a subject
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TPV/RTV - Rifabutin
Day 1: single dose Rifabutin Days 8-20: morning and evening doses of Tipranavir/Ritonavir Day 15: single dose Rifabutin |
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum plasma concentration of the analytes in plasma (Cmax)
Time Frame: up to 144 hours after drug administration
|
up to 144 hours after drug administration
|
Drug concentration of the analytes in plasma at 12 hours after administration (Cp12h)
Time Frame: up to 12 hours after drug administration
|
up to 12 hours after drug administration
|
Area under plasma concentration time curve from 0-12 hours (AUC0-12h)
Time Frame: up to 12 hours after drug administration
|
up to 12 hours after drug administration
|
Area under the plasma drug concentration-time curve from time zero to infinity of the analytes (AUC0-∞)
Time Frame: up to 144 hours after drug administration
|
up to 144 hours after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Oral clearance (CL/F)
Time Frame: up to 144 hours after drug administration
|
up to 144 hours after drug administration
|
Time of maximum concentration (Tmax)
Time Frame: up to 144 hours after drug administration
|
up to 144 hours after drug administration
|
Volume of distribution (V)
Time Frame: up to 144 hours after drug administration
|
up to 144 hours after drug administration
|
Apparent terminal half life (t1/2)
Time Frame: up to 144 hours after drug administration
|
up to 144 hours after drug administration
|
Number of subjects with adverse events
Time Frame: up to 24 days
|
up to 24 days
|
Number of subjects with abnormal changes in laboratory parameters
Time Frame: up to 21 days
|
up to 21 days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Antitubercular Agents
- Antibiotics, Antitubercular
- Ritonavir
- Tipranavir
- Rifabutin
Other Study ID Numbers
- 1182.44
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Tipranavir
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedHIV InfectionsUnited States, Puerto Rico
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimTerminated
-
Boehringer IngelheimApproved for marketingHIV InfectionsBelgium, Brazil, Canada, Denmark, El Salvador, Greece, Italy, Portugal, Spain
-
Boehringer IngelheimCompletedHIV InfectionsUnited States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Greece, Italy, Mexico, Netherlands, Portugal, Spain, Switzerland, United Kingdom
-
Boehringer IngelheimApproved for marketingHIV InfectionsUnited States, Australia, Belgium, Denmark, France, Greece, Ireland, Italy, Portugal, South Africa, Switzerland, United Kingdom
-
Boehringer IngelheimWithdrawn
-
Boehringer IngelheimCompleted